Products
AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Launched
4y ago
2022-03-29 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Convert PDF, edit them, split, rotate and more!

    Mar 29, 2022 · 4y agoLaunch page

Store data

Google Play · App Store
Google Play Google Play
Update date not synced
Rating
Rating not syncedRating count not synced
New ratings last mo
—
Price & IAP
FreeIAP data not synced
Current version
—Store metadata
App Store App Store
Update date not synced
Rating
Rating not syncedRating count not synced
New ratings last mo
—
Price & IAP
FreeIAP data not synced
Current version
—Store metadata

Store assets, rating histograms, install tiers, and screenshots are synced from Apple App Store, Google Play, and Chrome Web Store.

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2021-01-04

KeywordMonthly volume
pdf x6,100
pdfx4,560

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2022-03-29

Key pages

Weekly snapshots
pdfx.app/en/index.html Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does PdfX.app get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is PdfX.app and what platforms does it support?
PdfX.app is catalogued under PDF & Document Tools: Easy PDF Manipulation. Supported platforms: Mobile App.

Related products in this category

Writing & Documents / PDF & Document Tools

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.